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Available online 10 June 2013Abstract Gender differences have been described in osteoporosis with females having a higher risk of osteoporosis thanmales. The
differentiation of bonemarrow stromal cells (BMSCs) into bone or fat is a critical step for osteoporosis. Herewedemonstrated that loss
of the androgen receptor (AR) in BMSCs suppressed osteogenesis but promoted adipogenesis. The mechanism dissection studies
revealed that AR deficiency suppressed osteogenesis-related genes to inhibit osteoblast differentiation from BMSCs. Knockout of AR
promoted adipogenesis of BMSCs via Akt activation through IGFBP3-mediated IGF signaling, and the 5′ promoter assay and chromatin
immunoprecipitation assays further proved that AR could modulate IGFBP3 expression at the transcriptional level. Finally, addition of
IGF inhibitors successfully masked the AR deficiency-induced Akt activation, and inhibitions of Akt, IGF1, and IGF2 pathways reversed
the AR depletion effects on the adipogenesis process. These results suggested that AR-mediated changes in IGFBP3 might modulate
the IGF–Akt axis to regulate adipogenesis in BMSCs.
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http://dx.doi.org/10.1016/j.scr.2013.06.001IntroductionGender differences have been described in osteoporosis with
the female gender having higher risk of osteoporosis and
fracture than the male gender (Boling, 2001; Khosla et al.,
1999). The lineage differentiation balance between bone
and fat in bone marrow stromal cells (BMSCs) is a critical
determinant in development of osteoporosis (Rosen and
Bouxsein, 2006). Previous studies have shown that postmen-
opausal women have a higher risk of osteoporosis than men
939AR inhibits BMSC adipogenesis via IGFBP3at similar ages and that estrogen administration alleviates
osteoporosis in postmenopausal women, suggesting that the
fluctuation of estrogen levels is critical in bone absorption
and resorption (Lufkin et al., 1992). Similar phenotypes in
obesity were also observed in postmenopausal women as the
estrogen declined, indicating that estrogen affects adipo-
cyte differentiation (Carney, 2010; Freeman et al., 2010;
Ryan et al., 2002). However, estrogen levels cannot account
for the gender differences in male, since bone and fat in
male are mainly influenced by androgen (Alibhai et al.,
2012; Cilotti and Falchetti, 2009; Galvao et al., 2008; Keto
et al., 2012).
Clinical observations, from prostate cancer patients
treated with androgen deprivation therapy, have pointed
out that androgen/AR signaling is involved in osteoporosis
and obesity. The observations suggested that androgen
enhances osteogenesis and suppresses adipogenesis (Collier
et al., 2011). To better understand the AR function in
osteogenesis and adipogenesis, Kawano et al. and Yeh et al.
generated androgen receptor knockout (ARKO) mice and
clearly demonstrated that AR deficiency leads to osteopo-
rosis and increases obesity due to increased osteoclast
activity in bone and abnormal metabolism in white adipose
tissues (Kawano et al., 2003; Yeh et al., 2002). In addition,
Balkan et al. directly treated MC3T3-E1, an osteoblast
progenitor cell line, with androgen and concluded that
androgen could stimulate osteoblast differentiation (Balkan
et al., 2005). Kang et al. used ARKO mice to prove AR
deficiency leads to tissue-nonspecific alkaline phosphatase
down-regulation followed by decreased phosphate produc-
tion to cause reduced bone mineralization (Kang et al.,
2008). Similar results were obtained from the osteoblast
specific ARKO mouse showing that AR could stimulate
osteoblast differentiation and attenuate bone resorption
(Chiang et al., 2009; Notini et al., 2007). Recently, Tsai et
al. showed that ARKO mouse displayed osteoporosis with
decreased osteogenesis of BMSCs through down-regulation of
Runx2/Cbfa1 (Tsai et al., 2011). In our study, we used the
microarray assay to systematically analyze ARKO effects on
osteogenesis related genes and found AR plays a promoter
role in osteogenesis.
While AR effects on adipogenesis of BMSCs remain
elusive, using microarray analysis we found that the genes
in bone related categories, such as skeletal system develop-
ment, ossification, bone development, and osteoblast
differentiation, were down-regulated when AR was knocked
out in primary BMSCs, whereas the genes in the adipose
related category were not significantly altered in AR
knocked out BMSCs. With the molecular mechanism dissec-
tion, we found AR increases insulin-like growth factor
binding protein 3 (IGFBP3) through direct binding to its
promoter region. The IGFBP3 modulated by AR might then
participate in inhibiting Akt activation to cause less
adipocyte differentiation.Materials and methods
Cells, animals and reagents
Oil Red O and alizarin red powders were purchased from
Sigma Aldrich. Dihydrotestosterone (DHT) ELISA kit waspurchased from Enzo Life Science. Mlu I and Kpn I were
purchased from New England BioLabs. IGFBP3, AR, and
GAPDH antibodies were from Santa Cruz Biotechnology. Akt,
pAkt, ERK1/2, pERK1/2, JNK, and pJNK were purchased from
Cell Signaling Technology. Floxed AR/AR female mice were
established as we described in our previous publication (Yeh
et al., 2002). The EIIa Cre+/+ mice were purchased from
Jackson Lab. To establish wild type (WT) and ARKO mice, the
floxed AR/AR female mice were bred with EIIa Cre+/+ mice
to obtain the floxed AR+/y Ella Cre+/- as ARKO mice and the
AR+/y Ella Cre+/- as WT control. The primers used for
genotyping were as described previously (Huang et al.,
2012). All animal studies followed the “Guide for the Care
and Use of Laboratory Animals” (National Institutes of
Health publication). The protocols were reviewed and
approved by the University Committee on Animal Resources
of University of Rochester.Bone microcomputed tomography and
histomorphometry
12 weeks old WT and ARKO mice were euthanized with an
overdose of pentobarbital. The bones from the hind limbs
were taken out and cleaned with a scalpel to remove
muscles and connective tissues. The bone microcomputed
tomography and histomorphometry were performed and
analyzed as previously described (Kang et al., 2008).Fertility test
The fertility test was performed as previously described (Xu
et al., 2007). Basically, 3 WT and ARKO male mice were bred
with 2 proven fertile female mice. Male mice were kept for
10 days with 2 female mice and then female mice were
removed to other cages for 28 days to determine whether
they were pregnant. Pregnancy was assessed by the
generation of litters during that 28-day period. Fertility
results were expressed as average pup numbers/litter.Hematoxylin and eosin staining
Adipose tissues were dehydrated and embedded into paraffin
blocks. 5 tissue slides were prepared for hematoxylin and
eosin (H&E) staining. Briefly, tissue slides were deparaffined,
rehydrated, and stained with H&E as previously described (Lai
et al., 2012). After staining, tissue slides were dehydrated and
mounted with mounting medium. Images were taken with
Spot software using Nikon Camera and analyzed with Image
Pro Plus.Detection of DHT
Mice at 8 weeks old were euthanized and blood collected
using cardiac puncture (Lai et al., 2009). Sera were isolated
using the blood collection tubes by centrifuging the samples
for 30 min. 50 μl of sera was used to determine the DHT
levels following the instruction manual from Enzo Life
Science.
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Primary BMSCs were isolated from 8 weeks old mice following
the established method (Bianco et al., 2006). Colony forming
efficiency assays were performed following previous publica-
tions with some modifications (Castro-Malaspina et al., 1980;
Sacchetti et al., 2007). 2 × 105 mononucleated cells per well
were seeded onto 6-well plates. After culture for 21 days,
cells were fixed with methanol and washed with ddH2O. Cells
were stained with 1% methylene blue for 15 min and rinsed
with ddH2O twice. Images were taken with Nikon Camera.
Image Pro Plus was used to analyze the number of CFU-f
positive colonies (N50 cells).
Culture of human BMSCs
Human BMSCs were purchased from Millipore and maintained
with human BMSC expansion medium following the instruc-
tion manual. Cultured human BMSCs were analyzed within 10
passages.
Microarray analysis
WT and ARKO BMSCs were isolated and cultured from
8 weeks old male mice (Bianco et al., 2006). The hemato-
poietic lineage cells were depleted with the magnetic bead
isolation protocol as we previously described (Lee et al.,
2012). The kit was purchased from Miltenyi Biotec (Auburn,
CA). Briefly, 107 bone marrow cells were resuspended in
40 μl PBS buffer containing 2 mM EDTA and 0.5% BSA. 10 μl
biotin-antibody cocktails containing antibodies for hemato-
poietic lineage were mixed with resuspended cells and
incubated for 20 min on ice. 30 μl buffer and 20 μl
anti-biotin microbeads were incubated with samples for
20 min on ice. After incubation, the samples were put into
DynaMag™-2 Magnet (Invitrogen) for 2 min and the bound
beads were moved to each side. At this step, cells not bound
to beads were taken out and cultured for experiments. The
confluent cultured BMSCs were lysed to extract mRNA, and
10 μg fresh mRNA used to determine the whole gene changes
via mouse affymetrix microarray. The assay and analysis
procedures were as previously described (Faith et al., 2008).
The gene category was classified using DAVID bioinformatics
resources as previously described (Huang da et al., 2009).
Differentiation assay
Adipogenesis
BMSCs were seeded onto 6-well plates and cultured until
reaching confluence. The confluent cells were induced with
adipogenic media (DMEM + 10% FBS + 2 μg/ml Insulin + 1 μM
dexamethasone + 2 μM Rosiglitazone) for 6 days. Human
BMSCs were induced to differentiate into adipocytes using
the same differentiation media. The adipocytes containing
oil droplets were visualized with Oil Red O staining (Yu et
al., 2008).
Osteogenesis
BMSCs were seeded onto 6-well plates and cultured until
reaching confluence. The confluent cells were induced with
osteogenic media (DMEM + 10% FBS + 50 μg/ml ascorbicacid + 10 mM β-glycerophosphate). Human BMSCs were
differentiated into osteocytes with the same osteogenic
media. The mineralized osteocytes were visualized with
alizarin red staining.
Lentivirus infection
HEK-293T cells were used to produce lentivirus by
calcium-phosphate transfection. 12 μg lentivirus plasmid
(pLVTHM-scramble, pLVTHM-AR-siRNA, pWPI, pWPI-AR),
8 μg pCMVdeltaR8.91 containing GAG and POL, and 10 μg
pMD2.G containing VSVg) were used to produce virus in
60 mm2 dishes. The human siRNA-AR used in this study was
prepared as previously described (Chuang et al., 2009).
Culture media containing virus were collected 40 h after
transfection and filtrated through 0.45 μm filter to
remove cell debris or cells. The collected virus media
were used to infect cells in the presence of polybrene
(2 μg/ml) for 24 h. Media containing virus were removed,
fresh media were added to infected cells, and the cells
were cultured for another 3 days to allow target protein
expression. Since the lentiviral vectors express green
fluorescence protein (GFP), fluorescence microscopy was
used to monitor the infection efficiency via checking the
GFP signal.
Western blot analysis assay
Cell lysates were resolved with 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
blotted with antibodies mentioned before, and incubated
with correlated secondary antibodies conjugated with
horseradish peroxidase. Proteins were visualized according
to the manual instructions (Pierce ECL Western Blotting
Substrate, Thermo Scientific). Tubulin or GAPDH served as
loading control. The quantitation results were calculated
using Quantitative ONE software (Bio-Rad) and expressed as
relative value to loading control.
RNA extraction and real time quantitative PCR
(qRT-PCR)
Total RNAs were extracted with Trizol (Invitrogen) according
to the manufacturer's instructions. One μg mRNAs were used
to be reverse transcribed to cDNAs using Superscript III
(Invitrogen). Quantitative qRT-PCR was performed using
cDNA, specific gene primers, and SYBR green master mix
(BioRad) on an iCycler iQ Multi-color real-time PCR machine
(BioRad). qRT-PCR results were calculated as relative expres-
sions to the control and normalized to the housekeeping gene,
GAPDH. All primers used for qRT-PCR were summarized in
Supplemental Table 2.
Plasmid construction
The pGL3-IGFBP3-luciferase was constructed by ligating
pGL3-luciferase and IGFBP3 promoter region. The IGFBP3
promoter was cloned out using primers as described in
Supplemental Table 3. Both PCR product and pGL3-Luciferase
vector were digested with Kpn I and Mlu I restriction enzymes.
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16 °C and then transformed with DH5α. Transformed DH5α
were grown on the ampicillin selection agar to select out
positive clones that contain IGFBP3 promoter region hooked
with pGL3-luciferase.
Chromatin immunoprecipitation assay
Cultured WT and ARKO BMSCs were treated with 37%
formaldehyde to crosslink chromatin with proteins and 1 M
glycine was used to stop the reaction. Cells were washed
three times with PBS containing a cocktail of proteinase
inhibitors. Pellets were lysed with SDS lysis buffer and
sonicated as previously described (Kang et al., 2008). The
sonicated samples were pre-cleared with protein agarose
A/G and salmon sperm, diluted with ChIP dilution buffer,
and incubatedwith either IgG control or AR antibody overnight.
The samples were incubated with protein A/G-agarose to pull
down the chromatin complex. The pellets were washed with
low salt buffer, high salt buffer, immunocomplex wash
buffer, and TE buffer. The chromatins were eluted out from
the complex with elution buffer. The crosslinked chroma-
tins were reversed with NaCl and the products were
examined using DNA purification and PCR assay. The primers
used for PCR were as described in Supplemental Table 3.
The PCR product length of androgen response element (ARE)
2 is 279.
Statistical analysis
Values were expressed as mean ± standard deviation (S.D.).
The Student's t test was used to calculate p values. p values
were two-sided, and considered statistically significant
when b0.05.
Results
ARKO mice show osteoporosis and obesity
In order to clarify the AR role in osteoporosis and obesity, we
generated ARKO mice by mating floxed AR/AR female mice
with male mice expressing EIIa cre recombinase (Coumoul et
al., 2005), driven by the adenoviral EIIa promoter. Genotyping
data clearly showed both WT and ARKO mice expressed cre
and the WT mice expressed the intact AR form whereas the
ARKO mice showed AR deletion form, smaller than the intact
AR (Fig. 1A). Male reproductive organs showed phenotypes
consistent with our previous publication (Yeh et al., 2002).
The external genitalia showed feminized appearance,
microphallus, and the urethra showed hypospadia in male
ARKO mice. The scrotum of the ARKO mice was poorly
developed and showed female phenotype. ARKO mice also
showed agenesis of vas deferens, epididymis, seminal vesicle,
testis, and prostate organs (Fig. 1B). ARKO mice also had
smaller hearts than WT mice and this phenotype was
determined by heart weight/body weight (Fig. 1C). Consistent
with previous publications (Kang et al., 2008), ARKO mice
show osteoporosis, less trabecular bone formation than WT
(Fig. 1D) and obesity, larger white and brown adipocytes than
WT mice (Fig. 1E). ARKO mice also exhibit more fatty marrowthan WT mice (Fig. 1E). Infertility and dramatic decreases in
DHT levels were shown in ARKO mice (Figs. 1F and G). Similar
phenotypes were also observed from ARKO mice that were
generated by crossing floxed AR/AR female mice with male
mice expressing cre recombinase driven by β-actin promoter
(data not shown).
Bone developmental genes are down-regulated in
ARKO BMSCs
BMSCs contain a subset of stem cells that are able to form
osteoblasts and marrow adipocytes, and are able to
self-renew. To dissect the mechanism by which AR affects
stimulation of osteoblasts differentiation, a whole genome
microarray analysis was performed. The results revealed
that the ARKO BMSCs showed several down-regulated genes
in categories of skeletal system development, ossification,
bone development, and osteoblast differentiation (Figs. 2A,
B, and Supplemental Table 1), whereas no significantly
changed up-regulated genes were found in the category of
adipose development (Fig. 2A and Supplemental Table 1). To
confirm whether the down-regulated genes associated
with bone development are correlated with osteogenesis
of BMSCs, a mineralization assay testing osteoblast lineage
differentiation of BMSCs was performed. Indeed, using
alizarin red staining to quantify mineralization, ARKO
BMSCs displayed less mineralization than WT BMSCs
(Fig. 2C). A similar phenotype was also observed in
siRNA-AR-treated human BMSCs with less mineralization
than control human BMSCs (Fig. 2G). The ARKO effects in
osteogenesis were further confirmed via examining oste-
ogenesis markers expression and the results showed that
alkaline phosphatase 2 (Akp2), bone sialoprotein (IBSP),
and dentin matrix protein 1 (Dmp1) were expressed at
lower level in ARKO BMSCs than WT BMSCs (Figs. 2D−F).
Knockout of AR increases progenitor numbers of
BMSCs and their adipogenesis capacity
It has been shown that either increased adipocyte progen-
itor numbers or enhanced adipogenesis ability of BMSCs can
increase the final differentiated adipocyte numbers
(Bonyadi et al., 2003; Shin et al., 2009). To clarify how the
knockout of AR increases adipogenesis of BMSCs, colony
forming efficiency, a rough estimate of the number of
skeletal stem/progenitor cells, was performed. ARKO
BMSCs exhibited significantly higher numbers of colonies
than WT BMSCs as the quantification shows (Fig. 3A).
Consistent results were obtained using the adipocyte-
derived stromal cells (ADSCs) (Fig. 3B). To determine
whether knockout of AR also enhances the adipogenesis
potential of BMSCs, an adipogenesis induction experiment
was performed. The results revealed that the ARKO BMSCs
have more adipocyte formation than the WT BMSCs
(Fig. 3C). Expression profiles of adipogenesis markers
exhibited that fatty acid binding protein 4 (aP2), lipopro-
tein lipase (LPL), and PPARγ, were shown to be signifi-
cantly up-regulated in ARKO BMSCs (Fig. 3D). We also
observed a similar phenotype when we knocked down AR in
human BMSCs. Knockdown of AR in human BMSCs promoted
adipogenesis and adipogenic markers (Figs. 3E and F).
Figure 1 ARKO mice exhibit osteoporosis and enlarged adiocytes. (A) Genotyping of WT and ARKO mice. ARwt indicates intact AR and
ARdel is mutant AR. Cre bands are cre recombinase positive. (B) Upper panel: The external genitalia of male WT and ARKO mice. Lower
panel: The internal genitalia of WT and ARKOmice. Arrowheads and arrows indicate testis and bladder, respectively. (C) Representative
heart images of WT and ARKOmice. Graph is the quantification of heart weight over body weight (HW/BW). (D) Representative images of
trabecular bone fromWT and ARKO mice. Graph is bone volume over tissue volume (BV/TV). (E) Representative images of white adipose
tissues and brown adipose tissues of WT and ARKO mice. (F) Fertility test in WT and ARKO mice by measuring numbers of pups/litter
number. (G) DHT concentrations in WT and ARKO mice. For all studies, n = 6 from either WT or ARKO mice. *, p value b 0.05. **, p
value b 0.001. ***, p value b 0.0001. p values were generated with the Student's t test.
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could promote their ability to increase progenitor cell
numbers and adipogenesis, and thereby increase the
number of differentiated adipocytes.Figure 2 Identifying key regulators involved in AR-mediated osteo
Categories of signature genes that are positively correlated or regula
osteogenesis (blue color) and inhibit adipogenesis (*). (B) AR-media
objects are major categories of key factors. Green letters beside the
by using alizarin red staining in WT and ARKO BMSCs. (D) Akp2, (E)
BMSCs after 30 days of osteogenesis induction. (G) Alizarin red staini
which were manipulated with siRNA scramble control (sc) or siRNA-
***, p value b 0.0001. p values were generated with the Student's tKnockout of AR inhibits IGFBP3 activation of pAkt
Although we clearly documented that the knockout of AR
can stimulate BMSC adipogenesis potential, the mechanismgenesis and adipogenesis in BMSCs. (A) Classifications of top 10
ted by AR. Highlighted are genes previously reported to promote
ted key factors in bone development. Black letters within red
red objects are full gene names. (C) Osteogenesis determination
IBSP, and (F) Dmp1 expression were measured in WT and ARKO
ng was performed in human bone marrow stromal cells (hBMSCs),
AR (siAR). Quantitation is shown in the graph. *, p value b 0.05,
test.
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Figure 3 AR deficiency increases progenitors and adipogenic potentials of stromal cells. (A) Representative images of colonies in
WT and ARKO mice. Graph on the right is quantification of colony numbers. (B) Colony forming efficiency analysis was performed in
WT and ARKO ADSCs. Graph on the right is the quantification of colony numbers. (C) Adipogenesis analysis of WT and ARKO BMSCs
using Oil Red O staining. (D) aP2, LPL, and PPARγ2 mRNA levels were determined to quantify the extents of adipogenesis in WT and
ARKO BMSCs. (E) Oil Red O staining was performed in hBMSCs, which were manipulated with scramble control (sc) or siRNA-AR (siAR).
Quantitation result is shown in the graph. (F) aP2, LPL, and PPARγ2 were determined in hBMSCs, which were manipulated with either
sc or siAR. *, p value b 0.05. **, p value b 0.001. p values were generated with the Student's t test.
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factors (IGFs) can promote adipogenesis (Jia and Heersche,
2000; Oka et al., 1984). IGFBPs have been shown to suppress
adipogenesis (Baxter and Twigg, 2009; Chan et al., 2009;
Rajkumar et al., 1999) through either sequestering IGFs to
prevent its binding to IGF receptors (IGFRs) or interacting
with PPARγ to disrupt its adipogenic function (Chan et al.,
2009). Elevated IGFBP3 all leads to insulin resistance in
adipocytes via suppressing IGF1 induced pAkt (Chan et al.,
2005). In our microarray analysis, we found that knockout of
AR in BMSCs suppressed IGFBP3 expression, suggesting that
AR might inhibit IGF1-induced adipogenesis through promot-
ing IGFBP3. We therefore decided to further explore IGFBP3
related genes in WT and ARKO BMSCs. The q-RTPCR results
exhibited that the knockout of AR suppressed IGFBP3, but
increased IGF2 (Fig. 4A). There was no significant difference
in expressions of IGF1, IGF1R, and IGF2R in ARKO and WT
BMSCs (Fig. 4A). The IGFBP3 protein expression was decreasedin ARKO BMSCs (Fig. 4D). Similarly, knockdown of AR in human
BMSCs also resulted in suppression of IGFBP3 at themRNA level
(Fig. 4B) and at the protein level (Fig. 4C). To further dissect
the potential down-stream gene cascade modulated by the AR
mediated IGFBP3 signaling to influence adipogenesis process,
we investigated Akt, Erk1/2, and JNK pathways in BMSCs,
since it has been shown that Akt, Erk1/2, and JNK are involved
in adipogeneis (Bluher et al., 2009; Bost et al., 2005; Prusty et
al., 2002; Xu and Liao, 2004; Zhang et al., 2009). Interestingly,
the results showed that IGFBP3 negatively correlated with
activation of Akt, but not Erk1/2 and JNK (Figs. 4D–F). The
quantification results further validated this conclusion by
showing the significant difference in ratio of pAkt over Akt,
but not the ratios of pErk1/2 over Erk1/2 and pJNK over JNK
(Figs. 4D–F). The consistent down-regulation of pAkt by AR
was also observed in ADSCs (Fig. 4G). In order to determine
whether the pAkt is regulated by AR mediated IGFBP3
signaling, the IGF2 inhibitor (Chromeceptin) was used to
Figure 4 AR deficiency suppresses activation of Akt by IGFBP3 in BMSCs. (A) IGF1, IGF2, IGFBP3, IGF1R, and IGF2R were measured
using qRT-PCR in WT and ARKO BMSCs. n = 8 from either WT or ARKO mice. (B) IGFBP3 mRNA and (C) protein expression were
examined in hBMSC-sc and hBMSC-siAR. (D–F) IGFBP3, Akt, pAkt, Erk1/2, pErk1/2, JNK, and pJNK, were determined in BMSCs from 3
WT and ARKO mice. Quantification ratios of pAkt over Akt (pAkt/Akt), pErk1/2 over Erk1/2 (pErk/Erk), and pJNK over JNK (pJNK/JNK)
were determined and shown in graphs below gel images. (G) AR, pAkt, and Akt were measured in ARKO ADSCs transfected with vector
(V) and AR plasmids. (H) IGF inhibitor effects on Akt activation were tested in WT and ARKO BMSCs. pAkt expression is dose
dependently inhibited by IGF inhibitor in WT and ARKO BMSCs. *, p value b 0.05. p values were generated with the Student's t test.
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IGF2 is regulated by IGFBP3. We found pAkt was increased in
ARKO BMSCs and the IGF inhibitors successfully masked AR
mediated IGFBP3 signaling effects on pAkt expression in WT
and ARKO BMSCs (Hashimoto et al., 1997; Oesterreicher et al.,
2005; Wang et al., 2006; Xu et al., 1996) (Fig. 4H). Taken
together, the results in Fig. 4 clearly showed that knockout of
AR suppressed IGFBP3 activation of Akt signaling and
influenced the adipogenesis process.
AR enhances IGFBP3 transcription through direct
promoter binding
Although the IGFBP3-mediated activation of Akt signaling is
clear, the mechanism of AR regulation of IGFBP3 remains in
question. Therefore, we performed a promoter search to
identify putative AR binding elements (AREs) located on the
promoter region of IGFBP3. We found two potential AREs,
AGAAAAnnnnTGTCCT and ACTAAAnnnTGTTCT, which are
located at −794 to −819 and −1802 to −1816, respectively
(Fig. 5A). We constructed a pGL3-luciferase reporter
containing the IGFBP3 promoter region to directly test the
transcriptional regulation of IGFBP3 by AR (Fig. 5B). Using the
MMTV-luciferase construct which contains a strong ARE as a
positive control, we found AR enhanced IGFBP3 promotetransactivation with 2 fold induction in the presence of
androgen (Fig. 5C), suggesting that AR might directly bind to
the IGFBP3 promoter to modulate IGFBP3 transcription. To
further clarify whether AR directly binds to the IGFBP3
promoter, we used a ChIP assay to validate the potential
ARE sites. The input positive controls of WT and ARKO BMSCs
showed clear bands when using specific primers to amplify
ARE 2 located in the IGFBP3 promoter region. We found that
AR in WT BMSCs can bind to the ARE 2 of IGFBP3 promoter
region, but such binding was barely detected when the
ARKO BMSCs were used in the assay (Fig. 5D), suggesting
that AR in WT BMSCs was functional and able to regulate
IGFBP3 transcriptionally through direct binding to the
IGFBP3 promoter region.
Blocking of pAkt and IGF signaling reverses ARKO
effects on adipogenesis
We have identified that AR might stimulate IGFBP3 to affect
pAkt and IGF signaling. However, it was not clear whether
AR modulated adipogenesis through these pathways. To
further validate whether the AR mediated adipogenesis
is pAkt and IGF dependent, we used a pAkt inhibitor
(LY294002), an IGF1 inhibitor (Picropodophyllin, PPP), and
an IGF2 inhibitor (Chromeceptin, Chrome) to block
Figure 5 AR modulates IGFBP3 through promoter regulation. (A) Illustration of the IGFBP3 promoter region and 2 putative AREs,
ARE1 located from −819–794 and ARE2 located from −1816–1802. (B) Map of the constructed pGL3-IGFBP3 luciferase. A segment of
IGFBP3 promoter is from the location −2026 to +7. The two insertion sites are Kpn I and Mlu I. (C) Luciferase assays of MMTV-luciferase
(MMTV) and pGL3-IGFBP3-luciferase (IGFBP3 promoter) were performed in HEK-293T cells. 1 ng pRL-Tk was used as control for
luciferase. 0.5 μg vector, mAR, MMTV, and IGFBP3 promoter were transfected into HEK-293T cells either in the presence or absence
of 10 nM DHT. (D) Chromatin immunoprecipitation assay was performed in WT and ARKO BMSCs. Non-immune 10% input served as
positive control for IGFBP3 primers specific for ARE2. IgG was used to pull down chromatin complex as a negative control. AR antibody
was used to pull down chromatin complex as experimental targets. ***, p value b 0.0001. p values were generated with the Student's t
test.
946 C.-K. Huang et al.ARKO-mediated adipogenesis (Choi et al., 2006; Girnita et
al., 2008; Menu et al., 2007). We found that ARKO BMSCs
consistently had higher numbers of Oil Red O positively
stained adipocytes than WT BMSCs in the presence of
vehicle in three different experimental settings (Figs. 6A−
C). The adipogenesis markers, LPL, aP2, and PPARγ2 were
significantly increased in ARKO BMSCs compared to WT
BMSCs (Figs. 6A−C). However, treatment with the pAkt
inhibitor masked the difference in Oil Red O positively
stained adipocytes numbers between WT and ARKO BMSCs,
and significantly suppressed expression of LPL, aP2, and
PPARγ2 compared to vehicle-treated ARKO BMSCs (Fig. 6A).
Treatment with the two IGF inhibitors also significantly
abolished the ARKO effect and we no longer observed
differences in Oil Red O positively stained adipocytes
numbers (Figs. 6B, C). The LPL, aP2, and PPARγ2 expression
results confirmed the staining results. The observed
difference in adipogenesis markers between WT and ARKO
BMSCs (Fig. 6) disappeared after treatment with these
inhibitors, suggesting that the AR mediated suppression of
adipogenesis is partially mediated by IGF pathways.Discussion
Gender differences have been suggested in osteoporosis and
obesity for several decades. Although the effects of estrogen
and estrogen receptor signaling on osteoporosis and obesity
have been extensively investigated (Becker, 2010; Gennari
et al., 2007; Mauvais-Jarvis, 2011; Moverare et al., 2003;
Smith, 2005; Yi et al., 2008), the effects of androgen and AR
signaling on obesity and osteoporosis remain elusive.
Previous studies mainly focused on androgen and AR
signaling in studies relevant to osteoporosis, such as
osteoblast differentiation, mineralization, and osteoclast
activity. It has been shown that androgen induces osteoblast
differentiation and mineralization (Balkan et al., 2005) and
AR expression is gradually increased in differentiated
osteoblast (Wiren et al., 2002). In orchidectomized mice,
DHT treatment could reverse the orchidectomy-induced
trabecular bone loss phenotype (Moverare et al., 2003). AR
has suppressive functions in osteoclast activity to inhibit the
bone resorption (Kawano et al., 2003) and AR deficient mice
exhibit a bone loss phenotype in calvarial and femoral bones
Figure 6 Inhibition of IGFs and Akt signaling pathways reverse the AR deficiency effects on BMSC adipogenesis. (A) Oil Red O
staining was used to visualize oil droplets, and qRT-PCR was used to determine adipogenisis markers including LPL, aP2, and PPARγ2
in the differentiated adipocytes from WT and ARKO BMSCs in the presence of 10 μM LY294002 (Akt inhibitor). (B) 1 μM Chromeceptin
(Chrome), the IGF inhibitor and (C) 2 μM PPP (IGF I inhibitor) were used to treat WT and ARKO BMSCs, which were under adipogenic
induction and the adipogenic differentiation was monitored by Oil Red O staining and qRT-PCR to determine oil droplets and
adipogenesis markers. *, p value b 0.05. **, p value b 0.001 ***, p value b 0.0001. p values were generated with the Student's s test.
947AR inhibits BMSC adipogenesis via IGFBP3(Kang et al., 2008; Tsai et al., 2011). Other studies using
selective androgen receptor modulators (SARMs) to treat
ovariectomized or orchiectomized rats also demonstrated
that activation of AR signaling prevents bone loss (Kearbey
et al., 2007; Rosen and Negro-Vilar, 2002). In addition,
androgenic treatments enhanced apoptosis of osteoblasts
resulting in anabolic stimulation of new bone growth both in
vitro and in vivo (Wiren et al., 2006). In the present study,we established ARKO mice by breeding EIIa or Actb Cre mice
with floxed AR/AR mice and obtained the results that these
two kinds of ARKO mice exhibit consistent phenotypes with
bone loss. Moreover, our microarray analysis results demon-
strated that AR deficiency in BMSCs significantly represses
gene categories relevant to bone development and formation
including ossification, skeletal system development, and bone
development. Our studies on AR signaling in osteogenesis of
948 C.-K. Huang et al.BMSCs further support the concept that AR enhances bone
growth and inhibits osteoporosis via promoting BMSCs differ-
entiation into bone.
Androgen and AR signaling studies in obesity and
adipogenesis have demonstrated that androgen treatments
inhibit adipocyte differentiation and body fat formation in
both in vitro cell culture and in vivo animal models including
rodents and nonhuman primates (Blouin et al., 2008; Singh
et al., 2003, 2006; Varlamov et al., 2012; Zhang et al.,
2008). Androgen promotes the interactions among
β-catenin, AR, and T-cell factor 4 to suppress adipogenic
differentiation in 3T3-L1 cells (Singh et al., 2006). Androgen
inhibits rosiglitazone-induced adipogenesis in human BMSCs
(Benvenuti et al., 2012; Gupta et al., 2008). It is clear that
androgen inhibits adipogenesis either in preadipocytes from
white fat and BMSCs. However, AR is a transcriptional factor
that modulates gene expressions to coordinate body devel-
opment and function. It is essential to systematically
analyze how AR signaling in BMSCs transcriptionally affects
gene expressions in order to fully decipher AR function in
adipogenesis of BMSCs. Although previous studies have
compared gene changes between vehicle and androgen
treatments in adipocytes, none of them performed compar-
ison to BMSCs (Nantermet et al., 2008; Zhang et al., 2008).
Furthermore, it has been shown that charcoal stripped (CS)
fetal bovine serum (FBS) used in androgen treatment studies
still has residual testosterone levels (FBS: 2.7 ± 0.13 nM,
CS-FBS: 1.1 ± 0.39 nM) (Goldman-Johnson et al., 2008). In
this study, Goldman-Johnson et al. also demonstrated that
embryonic stem cells can synthesize testosterone at 0.53–
1.38 nM per 24 h. It does not seem to be suitable to dissect
AR signaling in adipogenesis of BMSCs and white adipocyte
derived preadipocytes by comparing vehicle and androgen
treatment in these conditions. Therefore, comparing gene
changes in BMSCs from WT and ARKO mice would elaborate
more accurate detailed molecular mechanism of androgen
and AR in the adipogenesis of BMSCs.
In our present study, we used BMSCs from WT and ARKO
mice and performed microarray assays to systematically
analyze the gene expression changes. We found AR depletion
in BMSCs significantly decreased expression of genes associ-
ated with bone development. However, the canonical
adipogenesis pathway in BMSCs was not directly altered by
AR knockout. Interestingly, depletion of AR in BMSCs
increased the number of progenitors and their adipogenic
potential to enhance adipocyte differentiation. When we
analyzed AR down-regulated genes, we hypothesized that
IGFBP3 could be a potential candidate modulating the
effect, since IGFBP3 might modulate IGF pathways to inhibit
adipogenesis. Indeed, we observed that ARKO BMSCs
expressed lower levels of IGFBP3, which in turn, activated
Akt signaling (induced by IGF pathways) as compared to WT
BMSCs. The luciferase and ChIP assays results both demon-
strated that AR positively and directly regulated IGFBP3
expression. Using IGF inhibitors to treat WT and ARKO
BMSCs, the ARKO effect in enhancing pAkt expression was
reversed, suggesting that AR promotes IGFBP3 to repress IGF
pathways and then to reduce pAkt activation, resulting in
less adipocyte differentiation. This conclusion was further
supported by the inhibitor studies using pAkt, IGF1, and IGF2
inhibitors that could block adipogenesis of WT and ARKO
BMSCs. The results showed that all three inhibitorssuccessfully reversed the AR knockout effect in adipocyte
differentiation through antagonizing Akt activation modu-
lated by AR-IGF–IGFBP3 signaling.
In summary, we demonstrated that AR promoted
osteogenesis and inhibited adipogenesis in BMSCs. Using
microarray analysis, we found AR positively regulates gene
categories relevant to bone development. This observation
partially explains the gender difference in osteoporosis,
since the female gender has lower androgen and AR
signaling. In the molecular mechanism study, we found AR
directly modulates IGFBP3 expression via promoter regula-
tion. In AR deficient BMSCs, down-regulated IGFBP3 might
result in loss of sequestration of IGFs and allow IGFs to
activate pAkt to stimulate adipogenesis. Meanwhile, treat-
ments with pAkt, IGF1 and IGF2 inhibitors successfully
reversed the AR depletion effects on adipogenesis,
suggesting that the AR mediated adipogenesis is through
the Akt and IGF pathways. Although there might be other
pathways contributing to the AR-mediated suppression of
BMSCs adipogenesis, our conclusions at least partially
explain how AR influences BMSCs adipogenesis. The study
provides the information related to AR mediated osteogen-
esis and adipogenesis of BMSCs and this information may be
relevant for clinical management of osteoporosis.Acknowledgments
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